NASDAQ:QURE uniQure Q4 2023 Earnings Report $14.90 -0.14 (-0.93%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$14.98 +0.08 (+0.57%) As of 04:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast uniQure EPS ResultsActual EPS-$1.53Consensus EPS -$1.54Beat/MissBeat by +$0.01One Year Ago EPSN/AuniQure Revenue ResultsActual Revenue$6.69 millionExpected Revenue$3.20 millionBeat/MissBeat by +$3.49 millionYoY Revenue GrowthN/AuniQure Announcement DetailsQuarterQ4 2023Date2/28/2024TimeN/AConference Call DateWednesday, February 28, 2024Conference Call Time2:00AM ETUpcoming EarningsuniQure's Q2 2025 earnings is scheduled for Thursday, August 7, 2025Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) uniQure Earnings HeadlinesuniQure's (QURE) Buy Rating Reaffirmed at HC WainwrightMay 30 at 3:09 AM | americanbankingnews.comuniQure (NASDAQ:QURE) Rating Increased to Hold at Wall Street ZenMay 26, 2025 | americanbankingnews.comHow he turns Zzzzzzz’s into $$$$$’sMost traders don’t realize this… But the closing bell means jack $#!&. They hear the bell and they think “time to go”... But when Tim Sykes hears the bell?May 30, 2025 | Timothy Sykes (Ad)uniQure Sees Unusually High Options Volume (NASDAQ:QURE)May 23, 2025 | americanbankingnews.comuniQure N.V. (QURE) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comuniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company ProgressMay 9, 2025 | globenewswire.comSee More uniQure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like uniQure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on uniQure and other key companies, straight to your email. Email Address About uniQureuniQure (NASDAQ:QURE) N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.View uniQure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles CrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns?Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Upcoming Earnings CrowdStrike (6/3/2025)Haleon (6/4/2025)Broadcom (6/5/2025)Oracle (6/10/2025)Adobe (6/12/2025)Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
